Originally developed in the 1990s, as a fat burning (lipolytic) compound, AOD9604 stimulates the breakdown or destruction of fat cells (lipolysis) and inhibits the metabolic formation of fat (lipogenesis) in animal studies
664,665 Clinically, corticobasal degeneration is manifested by movement deficits, impaired swallowing, speech, and memory
Enzyme-linked immunosorbent assay (ELISA) For the ligandreceptor affinity ELISA, the human FBXO22 protein served as an antigen to coat the 96-well plate at 4 C for 24 h
Provides neuroprotection FOXO4-DRI shows potential as a neuroprotective agent by targeting senescent cells that contribute to neuroinflammation and cognitive decline
The ChEMBL drug registry records tirzepatide at maximum phase 4 (approved), first approval 2022, parenteral, with a first-in-class GIP-agonist designation and a boxed-warning flag
Its ability to stimulate collagen and fibroblast activity makes it a powerful ally in anti-aging treatments and skin rejuvenation